What's (new) in the guidelines of the osteological societies of the German-speaking countries published in 2023
Authors:
Hess Zdeněk 1,2
Authors‘ workplace:
Fakulta zdravotnických studií Západočeské univerzity v Plzni
1; Ordinace všeobecného praktického lékařství, s. r. o., Mariánské Lázně
2
Published in:
Clinical Osteology 2024; 29(4): 136-142
Category:
Comments
Overview
The 2023 guidelines from German-speaking scientific osteological societies offer updated recommendations for osteoporosis prevention, diagnosis, and treatment, focusing on new risk factors, such as humeral fractures, cardiac and renal insufficiency, and chronic hyponatremia. The guidelines also consider additional factors, like immobility and HIV, and newly define bone density thresholds for initiating treatment. Romosozumab has been added as a therapeutic option to reduce the risk of vertebral and non-vertebral fractures. The improved fracture risk calculator now combines the two strongest risk factors with bone density measurements and shortens the predictive period to 3 years. The recommendations also include daily doses of vitamins D and K2, along with guidance for physiotherapy, rehabilitation, and managed care programs.
Keywords:
2023 guidelines – new risk factors – osteoporosis – romosozumab – updated recommen-dations for osteoporosis prevention/diagnosis/treatment
Sources
Literatura citovaná
Leslie WD, Berger C, Langsetmo L et al. [Canadian Multicentre Osteoporosis Study (CaMos) Research Group]. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 2011; 22(6): 1873–1883. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–010–1445–5>.
Bilezikian JP, Formenti AM, Adler RA et al. Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all? Rev Endocr Metab Disord 2021; 22(4): 1201–1218. Dostupné z DOI: <http://dx.doi.org/10.1007/s11154–021–09693–7>.
Sanders KM, Stuart AL, Williamson EJ et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303(18): 1815–1822. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2010.594>.
Smith H, Anderson F, Raphael H et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2007; 46(12): 1852–1857. Dostupné z DOI: <http://dx.doi,.org/10.1093/rheumatology/kem240>.
Bischoff-Ferrari HA, Freystätter G, Vellas B et al. [DO-HEALTH Research Group]. Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. Am J Clin Nutr 2022; 115(5): 1311–1321. Dostupné z DOI: <http://dx.doi.org/10.1093/ajcn/nqac022>.
Dai Z, McKenzie JE McDonald S et al. Assessment of the Methods Used to Develop Vitamin D and Calcium Recommendations-A Systematic Review of Bone Health Guidelines. Nutrients 2021; 13(7): 2423. Dostupné z DOI: <http://dx.doi.org/10.3390/nu13072423>.
Kimball SM, Holick MF. Official recommendations for vitamin D through the life stages in developed countries. Eur J Clin Nutr 2020; 74(11): 1514–1518. Dostupné z DOI: <http://dx.doi.org/10.1038/s41430–020–00706–3>.
Simes DC, Viegas CS, Araujo N et al. Vitamin K as a Diet Supplement with Impact in Human Health: Current Evidence in Age-Related Diseases. Nutrients 2020; 12(1): 138. Dostupné z DOI: <http://dx.doi.org/10.3390/nu12010138>.
Mladenka P Macakova K, Kujovska Krcmova L et al. Vitamin K – sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev 2022; 80(4): 677–698. Dostupné z DOI: <http://dx.doi.org/10.1093/nutrit/nuab061>.
Riphagen LJ, Keyzer CA, Drummen NE et al. Prevalence and Effects of Functional Vitamin K Insufficiency: The PREVEND Study. Nutrients 2017; 9(12): 1334. Dostupné z DOI: <http://dx.doi.org/10.3390/nu9121334>.
Saag KG, Petersen J, Brandi ML et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377(15): 1417–1427. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1708322>.
Kendler DL, Marin F, Zerbini CA et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double dummy, randomised controlled trial. Lancet 2018; 391(10117): 230–240. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)32137–2>. Erratum in: Lancet 2018; 392(10162): 2352. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32944–1>.
Gnant M, Pfeiler G, Dubsky PC et al. [Austrian Breast and Colorectal Cancer Study Group]. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386(9992): 433–443. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)60995–3>.
Abdel-Rahman O. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis. Expert Rev Anticancer Ther 2016; 16(8): 885–891. Dostupné z DOI: <http://dx.doi.org/10.1080/14737140.2016.1192466>.
Coleman R, Hadji P, Body JJ et al. [ESMO Guidelines Committee]. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020; 31(12): 1650–1663. Dostupné z DOI: <http://dx.doi.org/10.1016/j.annonc.2020.07.019>.
Smith MR, Egerdie B, Hernández Toriz N et al. [Denosumab HALT Prostate Cancer Study Group]. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361(8): 745–755. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0809003>.
Alibhai SM, Zukotynski K, Walker-Dilks C et al. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 167(5): 341–350. Dostupné z DOI: <http://dx.doi.org/10.7326/M16–2577>.
Poon Y, Pechlivanoglou P, Alibhai SM et al. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2018; 121(1): 17–28. Dostupné z DOI: <http://dx.doi.org/10.1111/bju.14015>.
Handoll HH, Cameron ID, Mak JC et al. Multidisciplinary rehabilitation for older people with hip fractures. Cochrane Database Syst Rev 2021; 11(11): CD007125. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD007125.pub3>.
Smith TO, Gilbert AW, Sreekanta A et al. Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery. Cochrane Database Syst Rev 2020; 2(2): CD010569. Dostupné z DOI: <http://dx.doi.org/ 10.1002/14651858.CD010569.pub3>.
Talevski J, Sanders KM, Duque G et al. Effect of Clinical Care Pathways on Quality of Life and Physical Function After Fragility Fracture: A Meta-analysis. J Am Med Dir Asso 2019; 20(7): 926.e1–926.e11. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jamda.2019.02.022>.
Literatura použitá necitovaná
Martineau AR, Jolliffe DA, Hooper R et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.i6583>.
Andresen C, Olson E, Nduaka CI et al. Action of calciotropic hormones on bone metabolism: role of vitamin D3 in bone remodeling events. Am J Immunol 2006; 2(2): 40–51. Dostupné z DOI: <https://doi.org/10.3844/ajisp.2006.40.51>.
Manson JE, Cook NR, Lee IM et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019; 380(1): 33–44. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1809944>.
Gillespie LD, Robertson MC, Gillespie WJ et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012; 2012(9): CD007146. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD007146.pub3>.
Saag KG, Pannacciulli N, Geusens P et al. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis Rheumatol 2019; 71(7): 1174–1184. Dostupné z DOI: <http://dx.doi.org/10.1002/art.40874>.
Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20): 2028–2039. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa071408>.
Saag KG, Wagman RB, Geusens P et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 2018; 6(6): 445–454. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(18)30075–5>.
Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60(11): 3346–3355. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24879>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyArticle was published in
Clinical Osteology
2024 Issue 4
Most read in this issue
- Charcot's osteoarthropathy or Sudeck's Syndrome? A case report
- Steroid contraception – the influence on bone metabolism
- Osteoporosis and liver diseases
- What's (new) in the guidelines of the osteological societies of the German-speaking countries published in 2023